On March 26, 2025 ImCheck Therapeuticsannounced reported updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 in Chicago, Illinois, USA (Press release, ImCheck Therapeutics, MAR 26, 2025, View Source [SID1234651473]). The poster presentation will provide efficacy, safety, pharmacodynamics and dose selection data on the novel γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of patients with newly diagnosed AML.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation at AACR (Free AACR Whitepaper) 2025 are:
Late-breaking abstract title: "γ9δ2 T-cell (γδTC) activation and azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) acute myeloid leukemia (AML) induces high rates of complete remission (CR): Preliminary efficacy, safety, pharmacodynamics (PD) and dose selection of ICT01 in the phase 1 study EVICTION"
Session: Phase 0 and Phase I Clinical Trials
Abstract number: CT024
Presenter: Abhishek Maiti, University of Texas MD Anderson Cancer Center
Authors:Abhishek Maiti, Pierre Peterlin, Daniel Morillo, Jose-Miguel Torregrosa-Diaz, Matthew Ulrickson, Agustin Penedo, Aude De Gassart, Elisabeth Wieduwild, Emmanuel Valentin, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Stephan Braun, Daniel Olive, Naval G. Daver, Sylvain Garciaz, Pierre-Yves Dumas
Date: Monday, April 28, 2025
Time: 9:00 am- 12:00 pm EST
Location: Poster Section 49 / Poster Board Number: 3
The AACR (Free AACR Whitepaper) poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting 2024 showing that ICT01 administered in combination with azacitidine and venetoclax demonstrated promising efficacy without compromising safety.
The AACR (Free AACR Whitepaper) poster will be available on ImCheck’s corporate website after the poster sessions have been opened.